Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma

Background: Atezolizumab plus bevacizumab therapy has high response rates in patients with unresectable hepatocellular carcinoma (HCC). The hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging (EOB-MRI) has been reported to be useful as an imaging biomarker for detecting β-caten...

Full description

Bibliographic Details
Main Authors: Ryu Sasaki, Kazuyoshi Nagata, Masanori Fukushima, Masafumi Haraguchi, Satoshi Miuma, Hisamitsu Miyaaki, Akihiko Soyama, Masaaki Hidaka, Susumu Eguchi, Masaya Shigeno, Mio Yamashima, Shinobu Yamamichi, Tatsuki Ichikawa, Yuki Kugiyama, Hiroshi Yatsuhashi, Kazuhiko Nakao
Format: Article
Language:English
Published: MDPI AG 2022-02-01
Series:Cancers
Subjects:
atezolizumab
bevacizumab
biomarkers
hepatocellular carcinoma
catenins
lenvatinib
Online Access:https://www.mdpi.com/2072-6694/14/3/827

Internet

https://www.mdpi.com/2072-6694/14/3/827

Similar Items